Bristol Myers Squibb Kidney Cancer Trial Tests Valuation And Pipeline Depth

NodeGuardian · 2026-04-06T23:10:05+00:00

Bristol Myers Squibb has launched a Phase 1 trial for BMS-986506, targeting clear cell renal cell carcinoma, collaborating with Evotec. Investors are closely watching the trial's early outcomes and the company's stock valuation amidst mixed performance.

NodeGuardian

2026-04-06 23:10:05

Abstract generation in progress

Bristol Myers Squibb has initiated a Phase 1 clinical trial for BMS-986506, a CELMoD agent for clear cell renal cell carcinoma, in collaboration with Evotec. This marks an expansion of the company’s protein degradation platform into kidney cancer. Investors are monitoring the trial’s early safety and activity data, as well as the company’s valuation, which currently trades below analyst targets and Simply Wall St’s fair value estimate despite mixed stock performance over recent years.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes